 Home > Medical News > Medical World News > The second batch of key projects of the China Drug Regulatory Science Action Plan was held

The second batch of key projects of the China Drug Regulatory Science Action Plan was held

 Last Update: 2022-10-19
 Source: Internet
 Author: User

Tags

science table elements

plan drug

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 23 and October 10, the State Food and Drug Administration held a report meeting on the second batch of key projects of the China Drug Regulatory Science Action Plan, listening to the research progress of each project in the three directions of drugs, medical devices and cosmetics, and deploying the key work
in the next stage.
Jiao Hong, director of the State Food and Drug Administration, attended and spoke at the meeting, and Xu Jinghe, Huang Guo, deputy directors of the State Food and Drug Administration, and the director of drug safety attended the meeting
.
The meeting was chaired
by Zhao Junning, deputy director of the State Food and Drug Administration.
The Party Central Committee and the State Council attach great importance to scientific and technological innovation and drug supervision, and the implementation of the scientific action plan for drug supervision by the State Food and Drug Administration is a practical action
to implement the deployment of the Party Central Committee and the State Council and strengthen regulatory capacity building through scientific and technological support.
In recent years, all relevant departments and bureaus and direct subordinates have attached great importance to and actively participated, highly integrated the implementation of key regulatory science projects with daily supervision, and achieved remarkable
results in the phased action plan for drug regulatory science.
Jiao Hong fully affirmed the achievements made since the implementation of the second batch of key projects of the Drug Regulatory Science Action Plan, and made arrangements
for the next stage of work.
First, improve the working mechanism and unite the strength of
all parties.
It is necessary to give full play to the advantages of the key laboratories of the State Administration and the regulatory scientific research base, encourage industry enterprises to actively participate in relevant work, and carry out in-depth regulatory scientific research
.
The second is to increase the intensity
of transformation of achievements.
It is necessary to strengthen organization and coordination, encourage the participation of scientific research personnel, increase the intensity of research, promote the transformation and application of research results, and produce more results, faster results, and good results
.
The third is to focus on key points and solve difficult problems
.
It is necessary to accelerate the promotion of regulatory scientific research in all links of review, inspection and supervision, and promote the further improvement
of the ability and level of supervision.
At the same time, it is necessary to strengthen guarantees and support in terms of funding guarantees, personnel title evaluation, performance evaluation, etc.
, better play the supporting role of regulatory science, and strive to create a scientific system of drug supervision with
Chinese characteristics.
Jiao Hong stressed that it is necessary to further integrate with the world, keep up with the latest development trends of international drug supervision, combine China's regulatory needs and industrial development needs, let regulatory scientific research help the high-quality development of China's pharmaceutical industry, improve people's health and well-being, and contribute Chinese wisdom and Chinese strength
to international drug supervision.
Relevant departments and bureaus of the State Food and Drug Administration, principal responsible comrades directly under the State Food and Drug Administration and relevant personnel attended the meeting
.

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.